C linical and experimental evidence suggests that estrogen plays important roles in physiological and pathological angiogenesis. In adult organisms, angiogenesis is virtually absent under normal conditions except in the female reproductive tract. The role of estrogen in uterine angiogenesis has been demonstrated by findings in the estrogen receptor ␣ (ER␣)-knockout (KO) mouse, in which angiogenesis is impaired, and by the demonstration that ER antagonists can inhibit angiogenesis. 1 The positive correlation between ER expression, angiogenic activity, and breast tumor invasiveness also supports the angiogenic effect of estrogen mediated by estrogen receptors, [2] [3] [4] In addition, the estrogen metabolite 2-methoxyestradiol has been shown to be a potent antiangiogenic agent. 5 
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Vascular endothelial cells express at least 2 estrogen receptors: ER␣ 6, 7 and ER␤. 8 Estrogen enhances endothelial cell activities in vitro 1, 9 and has favorable effects on ischemic neovascularization in vivo. 10, 11 In human studies, it was reported that postmenopausal hormone replacement therapy was associated with reduced risk of mortality after myocardial infarction (MI). 12 Tissue ischemia induces upregulation of angiogenic growth factors and mobilization of circulating cellular elements that together enable development of an accessory vasculature for organ survival. Recently, endothelial progenitor cells (EPCs) isolated from peripheral blood have been shown to incorporate into foci of neovascularization in the adult, ie, postnatal vasculogenesis. 13, 14 These circulating EPCs are derived from bone marrow and mobilized endogenously in response to tissue ischemia or exogenously by cytokine stimulation. [15] [16] [17] [18] Previous findings have suggested that estrogen also could augment the recruitment of EPCs for vascular repair. 11, 19, 20 Our laboratory showed that the effects of estrogen on EPC recruitment in vascular repair were endothelial nitric oxide synthase dependent. 11, 20 However, the potential role of estrogen receptor in EPC recruitment for myocardial microvascular repair has not been studied. In this study, we investigated the roles of ER␣ and ER␤ in estrogen-induced, EPCmediated tissue repair in the setting of acute MI.
Methods

Cell Culture
Mononuclear cells were isolated from mouse bone marrow and plated for EPCs as described previously 21, 22 and in the online Data Supplement. The rationale for using a culture method to enrich the EPC fraction of bone marrow cells is as follows: For phenotyping and assessing gene expression, circulating cells in the mouse are too scarce, thus mandating the use of a more abundant source of cells. A method has been developed and used repeatedly in our laboratory (and in multiple peer-reviewed publications 15, 16, 23 ) that favors the growth of cells with endothelial lineage capability while diminishing the non-EPC population. Medium was replaced with phenol red-free medium (EBM, Camblex, Walkersville, Md) with 5% charcoaldextran-treated fetal bovine serum (Biosource, Invitrogen, Carlsbad, Calif) at day 5 to remove the effects of estrogen-like activity of phenol red and estrogen derived from the serum. After 2 days in further culture, the cells were used as an EPC-rich cell population for cell function studies and real-time polymerase chain reaction (RT-PCR).
In Vitro Cell Function Assays (Proliferation, Migration, Tube Formation, and Adhesion Activity)
Cell proliferation was assessed by [3H]thymidine incorporation into DNA as described before. 24 Migration was measured in a modified Boyden's chamber. Tube formation assay was performed as described before using Matrigel-Matrix (BD Biosciences, San Jose, Calif). 25 The adhesion assay is described in the Data Supplement.
Animals
All mice used in this study were handled in accordance with the guidelines of the Animal Care and Use Committee at St Elizabeth's Medical Center of Boston (Mass). Female C57BL/6J mice (The Jackson Laboratory, Bar Harbor, Maine) were used as WT mice. Full details about ER␣-null mutant mice and ER␤-null mutant mice were given recently. 26 In ER␣-null mutant mice, exon 3 of ER␣ was deleted, and no ER␣ proteins were found in this strain. In ER␤-null mutant mice, exon 3 of ER␤ was deleted, and no ER␤ proteins were found in this strain. These mice are of C57BL/6 background.
Bone Marrow Transplantation Model
Female C57BL/6J mice 9 to 10 weeks old were studied. Mice underwent ovariectomy on day Ϫ35, followed by bone marrow transplantation (BMT) at day Ϫ28. WT, ER␣KO, or ER␤KO mice 8 to 12 weeks old were used as donors of the bone marrow. The BMT procedure was performed as described previously. 16, 21 At day Ϫ7, by which time the bone marrow of the recipient mice was reconstituted, BMT mice received either 17b-estradiol (E 2 ) pellets (Innovative Research of America, Sarasota, Fla) or placebo-containing pellets implanted subcutaneously into the dorsal neck region of the animals. To achieve typical E 2 levels found at mid-cycle, a 90-day release pellet containing 1.7 mg E 2 was used. Circulating E 2 levels in mice with the E 2 pellets and in mice with the placebo pellets were previously reported. 20 Seven days later (day 0), animals underwent MI surgery.
Surgical Procedure
MI was induced by permanent left anterior descending coronary artery ligation as described previously 11 using intraperitoneal injection of avertin 0.015 mg/kg and assisted ventilation (Harvard Apparatus, Holliston, Mass).
In Vivo Tissue Homing Assay
Female C57BL/6J mice 9 to 10 weeks old underwent ovariectomy at day Ϫ28, followed by either 1.7 mg E 2 pellet or placebo-containing pellet implantation, together with splenectomy at day Ϫ7. Seven days later (day 0), animals underwent MI surgery. Cultured EPCs were coincubated with 2 g/mL DiI-acLDL (Biomedical Technologies, Stoughton, Mass) for 1 hour, and 5ϫ10 5 EPCs were injected intravenously immediately after MI surgery. Hearts of these mice were harvested at the indicated time after MI surgery for histology.
Fluorescence-Activated Cell Sorting Analysis
To evaluate the number of circulating EPCs, 1 mL blood was taken at days Ϫ1, 7, and 28, and mononuclear cells were isolated by density centrifugation with Histopaque-1083 (Sigma-Aldrich, St Louis, Mo) for fluorescence-activated cell sorting analysis (Becton Dickinson, Franklin Lakes, NJ). The viable mononuclear cell population (2 to 4ϫ10 6 cells were available from 1 mL blood) was analyzed for the expression of Sca-1-FITC (BD PharMingen, San Diego, Calif) and Flk-1-PE (BD PharMingen). Isotype-identical antibodies served as negative controls (Jackson ImmunoResearch, West Grove, Pa).
Echocardiography
Left ventricular function was assessed by transthoracic echocardiography (SONOS 5500, Hewlett Packard, Palo Alto, Calif) at days Ϫ1, 7, 14, 21, and 28. Left ventricular end-diastolic dimension, left ventricular end-systolic dimension, and fractional shortening at the papillary muscle level of the left ventricle were measured, and the mean value of 3 measurements was determined for each sample.
Histological Analysis
In BMT models, hearts were harvested at day 28 for histological analysis. The explanted hearts were sliced in a bread-loaf fashion into transverse sections from apex to base and fixed with 4% paraformaldehyde. Tissues were stained for Masson's trichrome staining to measure the average ratio of fibrosis area to total left ventricular area.
Immunohistochemistry
The hearts of treated mice were harvested at predetermined times after surgery and frozen in optical coherence tomography compound (Sakura Finetek USA, Inc, Torrance, Calif). For capillary detection, sections were stained with mouse anti-CD31 antibody (BD PharMingen). For detection of vascular endothelial growth factor (VEGF), sections were incubated with mouse anti-VEGF antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif). Details are described in the Data Supplement.
Quantitative RT-PCR
RNA was collected from 8ϫ10 5 cells per sample with RNA STAT-60 (TEL-TEST, Inc, Friendswood, Texas). Total RNA was reverse transcribed with iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, Calif), and amplification was performed on the Taqman 7300 (Applied Biosystems, Foster City, Calif). Primer and probe sequences are described in the Data Supplement.
Determination of E 2 -Surface Binding With E 2 -Conjugated BSA-FITC E 2 -ER binding study was performed as previously described 27 with modification, as described in the Data Supplement.
Reporter Gene Luciferase Assay for Estrogen-Responsive Element-Dependent Transcription
EPCs were transiently transfected with estrogen-responsive element (ERE)-luciferase reporter construct using Fusene 6 transfection reagent (Roche, Palo Alto, Calif) according to the manufacturer's instructions, and luciferase activity was determined as described before. 28 
Statistical Analysis
All values are expressed as meanϮSE. Statistical significance was evaluated through the use of an unpaired t test for comparisons between 2 groups. For comparison among 3 or 4 groups, 1-factor analysis of variance was used, followed by an unpaired t test to compare 2 groups within them. When multiple time-point measurements were taken, repeated-measures analysis was done, followed by an unpaired t test. A value of PϽ0.05 was considered statistically significant.
The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
E 2 Effects on EPC Cell Function Are Abolished in ER-Knockout EPCs
First, we evaluated the role of ER expression on EPC cell function in vitro. In migration assays (Figure 1a) mol/L, PϽ0.01 versus without E 2 ). Finally, we evaluated tube formation, an established method to assess functional angiogenic activity in vitro. Capillary-like tube formation requires several biological activities such as endothelial cell proliferation, cell migration, protease secretion, and cell-to-cell interaction. As shown in Figure 1d and Ϫ8 mol/L) was severely impaired (PϽ0.001 versus WT EPCs).
E 2 Contribution to EPC Tissue Homing Is Impaired in ER-Knockout EPCs
From the results of the in vitro cell function assays, we hypothesized that E 2 could modulate chemotactic activity in EPCs via both ERs. Accordingly, we evaluated EPC homing in vivo in a tissue homing assay using mouse acute MI models. Incorporation of DiI-labeled WT EPCs, injected just after MI induction, was observed in the border zone of the ischemic myocardium (Figure 2a ) at day 3 (36.7Ϯ3.4 cells/ ϫ200 field). At day 5, the number of EPCs at the site increased (63.6Ϯ2.5 cells/ϫ200 field) and persisted until at least day 10 (day 7, 65.7Ϯ4.0 cells; day 10, 61.5Ϯ4.0 cells; Figure 2b ). Next, we compared WT, ER␣KO, and ER␤KO EPC incorporation at the border zone of the ischemic myocardium at day 7, choosing this time point as the approximate peak on the basis of pilot studies. Incorporation of WT EPCs in ovariectomized mice with placebo pellets was used as a negative control (40.2Ϯ3.7 cells). As shown in Figure 2c and 2d, the number of incorporated cells per ϫ200 magnification field was significantly higher in WT EPCs (72.5Ϯ1.3) compared with ER␣KO (42.4Ϯ1.5; PϽ0.001) and ER␤KO EPCs (55.4Ϯ1.8; Pϭ0.03).
E 2 Contribution to EPC Mobilization From Bone Marrow Was Impaired From ER-Knockout Bone Marrow
To evaluate the effect of ER-mediated effects on circulating EPC kinetics in vivo, peripheral blood was collected at serial time points after MI in WT, ER␣KO, and ER␤KO BMT models and prepared for fluorescence-activated cell sorting analysis. The light-scatter pattern of mononuclear cells was similar in WT, ER␣KO, and ER␤KO cells (Figure 3a) . As shown in Figure 3b , a significantly greater number of circulating Sca-1 ϩ /Flk-1 ϩ cells were observed in WT BMT mice 1 week after MI (2.87Ϯ0.13% of total mononuclear cells) compared with ER␣KO (2.03Ϯ0.18%; Pϭ0.004 versus WT BMT with E 2 pellet) and ER␤KO (2.62Ϯ0.07%; Pϭ0.02 versus WT BMT with E2 pellet) BMT mice.
Protective Effect of E 2 in MI Is Reduced in ER-Knockout BMT Model
Physiological and histological assessments were then performed after MI in WT, ER␣KO, and ER␤KO BMT mice. WT mice with WT BMT plus placebo pellets were evaluated as negative controls. Left ventricular end-diastolic dimensions and systolic function were not significantly different
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between WT BMT and ER mutant BMT mice early after MI (Figure 4a ). However, beginning 3 weeks after MI, echocardiography revealed better preservation of fractional shortening in the WT BMT mice compared with ER␣KO BMT mice (WT BMT versus ER␣KO BMT: Pϭ0.02 at 3 weeks after MI, Pϭ0.007 at 4 weeks after MI; Figure 4a , left).
Masson's trichrome-stained tissues in ER␣KO and ER␤KO BMT mice indicated marked dilation of the left ventricular cavity consistent with the echocardiographic measurements (Figure 4b ). The area of fibrosis was significantly less in WT BMT mice than in ER␣KO and ER␤KO BMT mice (WT BMT, 13.5Ϯ1.1%; ER␣KO BMT, 19.4Ϯ2.4%; ER␤KO BMT, 17.9Ϯ1.1%; Figure 4c ). WT BMT mice with placebo pellets were analyzed as negative controls (WT BMT with placebo, 21.7Ϯ0.8%). Capillary density at the border zone of ischemic myocardium 4 weeks after MI was significantly greater in WT BMT mice with E 2 compared with ER␣KO BMT and ER␤KO BMT mice with E 2 (WT BMT, 1718Ϯ75/mm 2 ; ER␣KO BMT, 1107Ϯ48/mm 2 ; ER␤KO BMT, 1567Ϯ50/ mm 2 ; Figure 4d and 4e). In WT BMT mice with placebo pellets, capillary density was 1136Ϯ83/mm 2 .
ER␣/ER␤ Expression and Binding Activity to E 2 on Mouse EPCs
In the above series of experiments, ER␣KO EPCs appeared to have a more prominent phenotype than ER␤KO EPCs. To better understand the potential mechanisms for Figure 5b and Figure 5c ). Because ER␤ expression was low by RT-PCR, we reevaluated it using other primer sets that were within exon 5 of the ER␤ sequence (Figure 5c , right). In WT EPCs, the relative expression of ER␤ versus 18S was again much lower than ER␣ expression (0.12Ϯ0.03). In ER␤KO mice, ER␤ exon 5 gene transcription was accelerated (13.2Ϯ0.27), which indicates that the gene was actually present in ER␤KO mice except exon 3, where the ER␤ gene was disrupted. In addition, E 2 10 Ϫ8 mol/L induces ER␣ mRNA upregulation in WT EPCs (Pϭ0.004) and ER␤KO EPCs (Pϭ0.015; Figure 5d ). Bovine serum albumin-FITC-tagged estradiol (E 2 coBSA-FITC) was used to investigate estrogen binding in WT, ER␣KO, and ER␤KO EPCs (Figure 5e and 5f). After 4 hours of incubation, 64.5Ϯ4.1% of cells were positive for FITC in WT EPCs, whereas 11.4Ϯ2.9% of cells were positive in ER␣KO EPCs (PϽ0.001). There were no significant differences in binding activity between WT and ER␤KO EPCs (58.8Ϯ3.0%). Preincubation with unlabeled E 2 
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Ϫ6 mol/L diminished E 2 coBSA binding (20.8Ϯ2.5%), indicating ligand specificity. As an additional measure of individual ER function, ERE-dependent transcription of the reporter gene luciferase was evaluated in EPCs from each genotype. As shown in Figure 5g , E 2 treatment (10 Ϫ8 mol/L) of WT EPCs led to a 35-fold increase in reporter activity over untreated cells. In contrast to WT EPCs, reporter activity was significantly decreased in EPCs from both ER␣KO and ER␤KO mice (PϽ0.01 and PϽ0.03, respectively), indicating that E 2 -induced, ERE-dependent gene transcription requires both ER␣ and ER␤.
E2 Upregulates VEGF Through ER␣ in EPCs
To investigate ER␣-associated gene expression, we evaluated the repertoire of angiogenic molecules expressed in EPCs by analyzing RNA extracted from WT and ER␣KO EPCs. Of injection of EPCs just after induction of myocardial injury, we observed that the incorporated WT EPCs, but not ER␣KO EPCs, expressed VEGF (Figure 6c ), corroborating the in vitro findings and providing further evidence that ER␣-mediated VEGF expression might represent a key feature of the E 2 -mediated EPC-derived effect on MI recovery.
Discussion
Previous studies performed in our laboratory indicated that E 2 could enhance the recruitment of EPCs and had favorable effects on neovascularization in ischemic tissues. 11 The focus of the present study was the role of ERs in activation of EPCs during ischemic neovascularization.
These data, from in vitro EPC functional assays, assessment of in vivo EPC homing to ischemic myocardium, and EPC mobilization from bone marrow after MI in mice in which the bone marrow had been replaced with ER␣KO or ER␤KO mutant marrow, indicate that both ER␣ and ER␤ are functional in EPC-mediated ischemic neovascularization.
The present findings further reveal that the effects of E 2 on EPC activation are mediated more prominently via ER␣ than ER␤. Prior studies of the roles of ⌭R␣ and ER␤ in mediating the macrovascular protective effects of estrogen acting via endothelial cells. 8,29 -31 including studies in transgenic mice in which either ⌭R␣ or ER␤ expression had been disrupted, have revealed that ⌭R␣, not ER␤, mediates the protective effects of estrogen after vascular injury. 30, 31 Our data indicate that certain microvascular effects of E 2 involving bone marrow-derived EPCs are mediated predominantly via ⌭R␣, but the data also provide evidence of a clear function for ER␤ in this setting.
Our data also provide several clues to explain the apparently disproportionate role of ER␣ in EPC-mediated ischemic neovascularization. First, we found that ER␣ mRNA expression was Ͼ10 times higher than ER␤. In agreement with previous evidence in mature endothelial cells, 32 physiological levels of E 2 induce ER␣ mRNA upregulation in EPCs, indicating that the ligand has potent effects on the expression of its own receptor. Moreover, FITC-conjugated E 2 -ER binding assay and reporter gene luciferase assay for ERE-dependent transcription support that ER␣ is a main functional receptor for E 2 in EPCs.
Further potential mechanisms of the ER␣-specific effects on EPCs were provided by gene expression profiling, which indicated that VEGF was markedly upregulated by E 2 42, 44 Our data indicate that this mechanism is not at play in EPCs.
The actual mechanism by which E 2 influences EPC kinetics through ER␤ remains unknown. Among 128 angiogenic genes investigated by gene array analysis, we could not find any candidates with consistent and specific expression differences between WT and ER␤KO EPCs. A more comprehensive search to identify previously unsuspected candidate genes is under way.
The findings of this report could be of interest for a variety of scientific reasons; however, the impact of our data resides to a large degree on the significant overall effect of estradiol on post-MI outcome. In the present investigation, we concentrated our studies on the mobilization, recruitment, and incorporation of bone marrow-derived cells into vascular structures; however, this paradigm alone may not offer the full explanation for the effect of E 2 . For example, we did not investigate the possibility that E 2 augmented other pathways of tissue repair such as mobilization and homing of cells that can differentiate into cardiomyocytes [45] [46] [47] and stimulation of local cardiac progenitors. 48 In the setting of acute myocardial injury, improved outcome may result via protection (eg, antiapoptosis) and via the full paradigm of tissue repair (ie, replacement of damaged structures). Tissue repair thus requires neovascularization, as documented in the present investigation; however, our studies do not exclude additional E 2 -mediated effects. Cardiac myocytes and fibroblasts are known to express ER, 49, 50 providing a mechanism for direct effects of E 2 on these components of the tissue response to MI.
Finally, beyond the specific findings of this report, these data have important implications because they provide additional evidence of the critical importance of the phenotype of bone marrow-derived EPCs in regulating ischemic tissue repair and suggest that modulation of EPC phenotype may have important therapeutic implications.
CLINICAL PERSPECTIVE
Despite the negative results of recent randomized trials of hormone replacement therapy for the prevention of cardiovascular events, abundant clinical and preclinical data provide evidence of a protective effect of estrogen. For example, premenopausal women are significantly less likely to experience cardiovascular events than are age-matched men, and premature (eg, surgical) menopause is associated with an increased incidence of coronary disease. Most recently, mutations in certain estrogen receptors in humans have been associated with increased incidence of cardiac disease. The present study examined the role of estrogen receptors (ERs) ␣ and ␤ in the improved recovery from myocardial infarction resulting from estradiol (E 2 ) administration. The data reveal that although both ER␣ and ER␤ mediate the effects of E 2 on myocardial infarction recovery, ER␣ appears to be more critical. These data may lead to the identification of new therapeutic targets for post-myocardial infarction recovery by dissecting the effects of ER␣ and ER␤. With the knowledge that ER␣ is more important in the overall benefit of E 2 , specific downstream signaling pathways that directly mediate the benefit of E 2 may be targeted pharmacologically, thereby permitting development of a therapy that mimics the benefits of E 2 without the side effects (thrombosis, gynecomastia in men, etc) of the natural or synthetic hormone.
